Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2008)

Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults

  • Coleman Rotstein,
  • Lael Cragin,
  • Michel Laverdière,
  • Gary Garber,
  • Eric J Bow,
  • Alissa Scalera,
  • Craig Roberts,
  • Sonja V Sorenson,
  • the Canadian Expert Panel

DOI
https://doi.org/10.1155/2008/161835
Journal volume & issue
Vol. 19, no. 3
pp. 219 – 226

Abstract

Read online

BACKGROUND: Candidemia is a common cause of nosocomial bloodstream infection. When selecting therapeutic treatments for candidemia, cost-effectiveness is an important consideration. The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia.